Zhejiang's first batch of bivalent HPV vaccines are in place

Medical Network October 26, cervical cancer is a major threat to women's health, human papillomavirus (HPV) vaccination is the first step of cervical cancer prevention recommended by the World Health Organization. On July 31, 2017, the bivalent HPV vaccine produced by GlaxoSmithKline became the first approved HPV vaccine in mainland China. The bivalent HPV vaccine is recommended for women aged 9 to 25, at the expense of the masses. For the voluntary vaccination, a 3-dose immunization program is used.

It is reported that Zhejiang CDC in September 2017 completed the HPV vaccine and government procurement, the province's counties and districts CDC HPV vaccine can be purchased at the Zhejiang Provincial Government procurement cloud platform. The vaccine is targeted at human papillomavirus types 16 and 18, which are responsible for about 70% of cervical cancer worldwide.

On the 24th, the reporter learned from the Zhejiang Provincial Center for Disease Control and Prevention that the first batch of HPV vaccines in Zhejiang had been put in place on the 23rd. The Third Hospital of Yinzhou District, Ningbo City, Zhejiang Province and the Community Health Service Center of Chengnan Street, Nanhu District, Jiaxing City, Zhejiang Province, ushered in the first place. Citizens vaccinated with cervical cancer; On the 24th, the Community Health Service Center of Caihe, Kaixuan, Sijiqing and Pengyu Streets in Jianggan District, Hangzhou City, Zhejiang Province also welcomed the first citizen who was vaccinated against cervical cancer.

At present, 63 county-level CDCs in Zhejiang Province have completed HPV vaccine procurement , and nearly 50,000 HPV vaccines will be in place. The citizens can be vaccinated at nearby town hospitals, health centers, and community health service centers.